NICE rejects Bayer liver cancer drug again9th September 2009
The National Institute for Health and Clinical Excellence (NICE) has again rejected Bayer's drug Nexavar for treating liver cancer on the NHS.
This is despite a revised charging scheme from the company and is a further setback to Bayer and its partner Onyx Pharmaceuticals, which have already seen Nexavar turned down by the NICE to treat kidney cancer. Bayer said the decision on its drug, which is known generically as sorafenib, for the treatment of hepatocellular carcinoma was a blow to patients.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: NICE rejects Bayer liver cancer drug again
Author: Mark Nicholls
Article Id: 12602
Date Added: 9th Sep 2009